Life Sciences_YIJING CAPITAL

Noah AI is an innovative company focused on generative AI applications, building AI-native products and agent application systems for enterprises and developers. It advances foundation models, multimodal interaction, and AI content production to commercialize AI in workplace collaboration, content creation, and enterprise services

Artivila is a computational chemistry-driven drug developer founded by a former Pfizer chief scientist returning to China. It has strong AI-assisted pharmaceutical R&D capabilities. Computational chemistry and AI improve efficiency, support research teams, and increase the likelihood of success. It has established multiple small-molecule immuno-oncology pipelines.

Medical AI develops full-stack AI solutions designed to address real-world clinical needs and improve the precision and efficiency of medical practice. Leveraging medical image recognition and deep learning technologies, its solutions have been adopted by more than 1,000 medical institutions, supporting AI-enabled workflows across imaging quality control, diagnostic analysis, report generation, clinical treatment, research, education, and training

Vbiosci focused on the R&D, manufacturing, and commercialization of high-end veterinary biological products. The company has established proprietary subunit and genetic engineering vaccine technologies, with a development pipeline spanning poultry, livestock, and companion animals. Its subsidiary, YSK BIOSCIENCES CO., LTD., independently develops and manufactures key production materials, including serum-free media, purified excipients, and novel adjuvants.

Taichu is a biotechnology enterprise distinguished by its core competitive advantage in "CRO+CDMO integrated services", specializing in providing end-to-end technical solutions for global innovative drug development spanning from early-stage discovery through preclinical research

Keythera Pharmaceuticals is a clinical-stage biotech fim focused on pioneering small molecule drugs that efectively combatcancers and autoimmune disorders. To build a robust portfolio of products, the company emplys a strategy that leverages itsaffinity based high throughput screening technological platform. By doing so, the company aims to expedite the process ofdiscovering and developing new drugs while also ensuring distinctiveness within its product pipelines

Hanyu Medical focuses on the development of minimally invasive surgical catheters for structural heart disease. As transcatheter therapies for structural heart disease continue to advance, precision catheter technologies—particularly steerable catheters—have become critical to minimally invasive procedures. Since its founding, Hanyu Medical has developed a broad portfolio of products, including delivery systems for mitral and tricuspid valve repair devices and prosthetic valves, pulsed field ablation (PFA) systems, occluder delivery systems, transseptal puncture systems, and endoscopic catheters. The company has also established a manufacturing system compliant with ISO 13485 standards. Its catheter products have been adopted in clinical practice, enabling safer, less invasive, and more precise procedures for patients. Hanyu Medical also provides catheter design, R&D, and OEM manufacturing services

ZGC Shuimu Medical, It is committed to accelerating the process of registration and listing of innovative medical device products, and solving the "last mile" problem of industrialization for innovative medical device companies. The Group is the chairman unit of the Clinical Trial Branch of the China Association for Medical Devices Industry, the executive vice chairman unit of the Application Evaluation Branch of the China Medical Equipment Association, and the chairman unit of the Medical Device Committee of the Beijing Pharmaceutical Association

OUR United develops integrated precision radiotherapy solutions, with three strategic platforms spanning stereotactic radiosurgery, X/γ integrated radiotherapy, and digital oncology. Its iSRS platform supports stereotactic radiosurgery with Gamma Knife-level precision; TaiChiRT integrates X-ray and gamma-ray radiotherapy and has been recognized as a Breakthrough Device by the U.S. FDA; and DOSS is a cloud-based digital oncology platform designed to enable connected diagnostic and treatment services. Through proprietary technologies and a robust intellectual property portfolio, OUR United is advancing more precise, intelligent, and accessible radiotherapy solutions

CytoNiche is revolutionizing the Cell and Gene Therapy (CGT) industry with our scalable 3DFloTrix technology, offering comprehensive solutions for CGT manufacturing.Our product portfolio includes GMP-grade dissolvable microcarriers, serum-free media formesenchymal stromal/stem cells, and a complete suite of GMP-compliant equipment andconsumables